A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer
Laychiluh Bantie, Solomon Tadesse, Jimma Likisa, Mingfeng Yu, Benjamin Noll, Gary K. Heinemann, Noor A. Lokman, Carmela Ricciardelli, Martin K. Oehler, Andrew Beck, Rupal Pradhan, Robert Milne, Hugo Albrecht, Shudong Wang
Topics & Concepts
PalbociclibCancer researchOvarian cancerPI3K/AKT/mTOR pathwayMedicineIn vivoCancerCell cycleCell growthCyclin ECyclinApoptosisBiologyInternal medicineBreast cancerBiochemistryMetastatic breast cancerBiotechnologyAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysCancer Mechanisms and Therapy